Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hellenic Breast Surgeons Society
* Patients must have completed at least 5 years and not more than 7 years of continued treatment with tamoxifen (20 mg/day), while tamoxifen could have been discontinued up to 6 months prior to study entry.
* A substudy (ATENA lipid substudy)is designed to evaluate changes in the patients' serum lipid profile during study treatment.
Age
18–80
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
postmenopausal women only
histologically confirmed stage I-IIIA primary adenocarcinoma of the breast
estrogen and/or progesterone receptors positive or unknown
patients should have undergone surgery with a curative intent
patients must have completed at least 5 years and not more than 7 years of continued treatment with tamoxifen (20 mg/day), while tamoxifen could have been discontinued up to 6 months prior to study entry
Absence of any evidence of local or distant metastatic disease was required prior to randomization
You may not be if
DCIS, bilateral breast cancer, evidence of metastasis, ER and Pgr negative
Clareo Health | Adjuvant Post-Tamoxifen Exemestane Trial
